AP NEWS

Nemaura Announces License Agreement for 3 New Transdermal Patch Developments, and 48 Hour Diclofenac Patch Debut at CPhI Madrid

September 17, 2018

LOUGHBOROUGH, England--(BUSINESS WIRE)--Sep 17, 2018--Nemaura Pharma today announced it has entered into a license agreement with a Global Pharma Company to develop 3 new Transdermal Patch products. These patches address a multi-Billion dollar market and the agreement reflects the confidence placed in Nemaura’s ability to deliver complex dosage formulations. Previously Nemaura developed a daily transdermal patch for a CNS indication, which successfully completed clinical studies, and ANDA subsequently submitted to the FDA.

Nemaura Pharma is a UK based specialist Biotech Company with over 20 products in development, including several complex injectables, using proprietary and differentiated delivery platforms. The Company is head-quartered in the University town of Loughborough, and has several development laboratories as well as a GMP clean room suite and IMP license for the manufacture and supply of transdermal, topical, and aseptically manufactured injectable products using gassed isolation technology.

The company will be exhibiting at CPhI Madrid between the 9 th and 11 th October, stand 2F63 where Nemaura will be debuting its 48 hour sustained released Diclofenac gel patch. The company’s CEO Dr Chowdhury, and Director of Strategic Alliances Dr Wessling will be present for meetings.

In 2016, Nemaura received Frost & Sullivan recognition of its advanced micro-needle capability in skin drug delivery, and in 2018 it received the UK Medilink National Award for Drug Delivery. Nemaura aims to be one of the leading pharmaceutical technologists in this fast growing market, which is expected to be worth over £35billion within the next 5 years.

For Business Development enquiries and to arrange meetings at CPhI Madrid 2018: bd@nemaura.co.uk

About Nemaura Pharma

www.nemaura.co.uk

Founded in 2005, Nemaura Pharma is a private specialist biotech company with headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.

The company employs multi-disciplinary teams of scientists and engineers working in cutting-edge innovative drug formulation and medical device technologies designed to radically improve the way drugs are administered through the skin. It has patents secured or pending in multiple countries across numerous patent families.

Cautionary Statement Regarding Forward-Looking Statements.

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005386/en/

CONTACT: Nemaura Pharma

Dr Werner Wessling

bd@nemaura.co.uk

Telephone 01509 222912

KEYWORD: UNITED KINGDOM EUROPE SPAIN

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL

SOURCE: Nemaura Pharma

Copyright Business Wire 2018.

PUB: 09/17/2018 09:14 AM/DISC: 09/17/2018 09:13 AM

http://www.businesswire.com/news/home/20180917005386/en

AP RADIO
Update hourly